← Back to Search

Radiation Therapy

Adaptive Radiation Dose Escalation for Non-Small Cell Lung Cancer (PET-BOOST Trial)

N/A
Waitlist Available
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Patients with Eastern Cooperative Oncology Group (ECOG) status 0-2 within 4 weeks of randomization
Patients who are at least 18 years old and are able to consent
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights

PET-BOOST Trial Summary

This trial is testing whether a higher dose of radiation to areas of the tumor that are more active will reduce the rate of the cancer coming back in 2 years.

Who is the study for?
Adults with locally advanced non-small cell lung cancer who can undergo chemoradiotherapy, have a certain level of physical fitness (ECOG status 0-2), and tumors visible on scans. Excluded are those with poor respiratory function, significant recent weight loss, inadequate bone marrow reserve, other active cancers, severe heart or lung conditions, liver issues, pregnancy, or AIDS.Check my eligibility
What is being tested?
This phase II trial is testing if increasing the radiation dose to parts of the tumor that show more activity on PET scans can lower the chance of cancer returning within two years. Patients will either receive standard chemoradiotherapy or an intensified version targeting these active tumor areas.See study design
What are the potential side effects?
Chemoradiotherapy may cause side effects like fatigue, skin irritation at the treatment site, nausea and vomiting. The higher radiation doses could potentially increase these effects and might also lead to more serious complications in nearby organs.

PET-BOOST Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I can care for myself and am up and about more than 50% of my waking hours.
Select...
I am 18 years or older and can give my consent.
Select...
I will be treated with both chemotherapy and radiation as my main treatment.
Select...
My tumor or lymph node is at least 10mm large as shown on a CT scan.

PET-BOOST Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Reduction of local-regional failure rate
Secondary outcome measures
Dose Escalation Feasibility
Dose-Response Characterization
Grade 3-5 Toxicity Rate
+5 more

PET-BOOST Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Chemoradiotherapy with Integrated Boost DoseExperimental Treatment1 Intervention
Patients randomized to the experimental arm will receive radiotherapy (5x per week) with an integrated boost dose of up to 85Gy in 30 fractions to tumor subvolumes, with concurrent cisplatin and etoposide chemotherapy.
Group II: ChemoradiotherapyActive Control1 Intervention
Patients randomized to the standard arm will receive radiotherapy (5x per week) of 60 gray (Gy) in 30 fractions with concurrent cisplatin and etoposide chemotherapy.

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
654 Previous Clinical Trials
413,107 Total Patients Enrolled

Media Library

Chemoradiotherapy (Radiation Therapy) Clinical Trial Eligibility Overview. Trial Name: NCT02788461 — N/A
Non-Small Cell Lung Cancer Research Study Groups: Chemoradiotherapy, Chemoradiotherapy with Integrated Boost Dose
Non-Small Cell Lung Cancer Clinical Trial 2023: Chemoradiotherapy Highlights & Side Effects. Trial Name: NCT02788461 — N/A
Chemoradiotherapy (Radiation Therapy) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02788461 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many locales are currently overseeing this clinical endeavor?

"Currently, there are 7 medical centres hosting this clinical trial. Out of the participating sites, some cities include London, Quebec and Newmarket with additional locations available too. It is advised to select a nearby clinic in order to decrease travel demands for participants."

Answered by AI

Are any new individuals being enrolled in this trial at the present time?

"Per the clinicaltrials.gov website, patient recruitment for this study is still in progress; it was first launched on May 1st 2016 and its details were last updated on April 7th 2022."

Answered by AI

What is the total cohort size of this experiment?

"This trial necessitates the enrolment of 78 qualified individuals. Prospective participants can apply at London Regional Cancer Program in London, Ontario or CHU de Quebec - L'Hôtel-Dieu de Québec in Quebec, Ont."

Answered by AI
~9 spots leftby Apr 2025